Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, ...

Please provide your email address to receive an email when new articles are posted on . Results showed 22.7% of patients who reinitiated infliximab after biosimilar use discontinued treatment due to ...

Oct. 11 -- THURSDAY, Oct. 9 (HealthDay News) -- Infliximab (Remicade) alone or in combination with azathioprine is more effective in treating Crohn's disease than azathioprine alone, researchers ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...

Dec. 22, 2004 — The U.S. Food and Drug Administration (FDA) and Centocor have warned healthcare professionals via letter regarding risks of hepatotoxicity and pneumonia associated with the use of ...

Starting on infliximab right after diagnosis leads to better outcomes than waiting longer for this medication, a new study suggests. Starting infliximab (Remicade) immediately after Crohn’s diagnosis ...

NEW YORK (Reuters) - Crohn's disease patients taking Johnson & Johnson's Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those ...

JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) ...

Please provide your email address to receive an email when new articles are posted on . Severe disability and all-cause mortality were lower at 6 months among patients given infliximab. No ...

Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based ...

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

The latest clinical trial data for subcutaneous (SC) infliximab (CT-P13 SC), presented at the United European Gastroenterology (UEG) Week 2023 in Copenhagen, further support the potential of CT-P13 SC ...